

BC

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
26 June 2003 (26.06.2003)

PCT

(10) International Publication Number
WO 03/051822 A1(51) International Patent Classification⁷: C07C 235/20, (74) Agent: ASTRAZENECA; Global Intellectual Property,
A61K 31/16, A61P 3/00 Mereside, Alderley Park, Macclesfield, Cheshire SK10
4TG (GB).

(21) International Application Number: PCT/GB02/05744

(22) International Filing Date:
18 December 2002 (18.12.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0104334-8 19 December 2001 (19.12.2001) SE

(71) Applicant (for all designated States except MG, US): ASTRAZENECA AB [SE/SE]; S-151 85 Sodertalje (SE).

(71) Applicant (for MG only): ASTRAZENECA UK LIMITED [GB/GB]; 15 Stanhope Gate, London, Greater London W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ALSTERMARK LINDSTEDT, Eva-Lotte [SE/SE]; Molndal, S-431 83 (SE). OLSSON, Anna, Christina [SE/SE]; Molndal, S-431 83 (SE). LI, Lanna [SE/SE]; Molndal, S-431 83 (SE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SUBSTITUTED PHENYLPROPIONIC ACID DERIVATIVES AS AGONISTS TO HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA (PPAR)

WO 03/051822 A1

(57) Abstract: The present invention provides the S enantiomer of a compound of formula (I); wherein R¹ represents 2,4-difluorophenyl or cyclohexyl as well as pharmaceutically acceptable salts, solvates, crystalline forms and prodrugs thereof, to processes for preparing such compounds, to their utility in treating clinical conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance, to methods for their therapeutic use and to pharmaceutical compositions containing them.

SUBSTITUTED PHENYLPROPIONIC ACID DERIVATIVES AS AGONISTS TO HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA (PPAR)

Field of the invention

The present invention relates to certain novel (2S)-3-(4-{2-[amino]-2-oxoethoxy}phenyl)-
5 2-ethoxypropanoic propionic acid derivatives, to processes for preparing such compounds,
to their the utility in treating clinical conditions including lipid disorders (dyslipidemias)
whether or not associated with insulin resistance and other manifestations of the metabolic
syndrome, to methods for their therapeutic use and to pharmaceutical compositions
containing them.

10

Background of the invention


The metabolic syndrome including type 2 diabetes mellitus, refers to a cluster of
manifestations including insulin resistance with accompanying hyperinsulinaemia, possibly
15 type 2 diabetes mellitus, arterial hypertension, central (visceral) obesity, dyslipidaemia
observed as deranged lipoprotein levels typically characterised by elevated VLDL (very
low density lipoproteins), small dense LDL particles and reduced HDL (high density
lipoprotein) concentrations and reduced fibrinolysis.

20 Recent epidemiological research has documented that individuals with insulin resistance
run a greatly increased risk of cardiovascular morbidity and mortality, notably suffering
from myocardial infarction and stroke. In type 2 diabetes mellitus atherosclerosis related
conditions cause up to 80% of all deaths.

25 In clinical medicine there is awareness of the need to increase the insulin sensitivity in
patients with the metabolic syndrome and thus to correct the dyslipidaemia which is
considered to cause the accelerated progress of atherosclerosis. However, currently this is
not a universally accepted diagnosis with well-defined pharmacotherapeutic indications.

30

The S-enantiomer of the compound of formula C below




2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl]propanoic acid, is disclosed in PCT Publication Number WO99/62872. This compound is reported to be a modulator of peroxisome proliferator-activated receptors (PPAR, for a review of the PPARs see T. M.Willson et al , J Med Chem 2000, Vol 43, 527) and has combined PPAR α /PPAR γ agonist activity (Structure, 2001, Vol 9, 699, P. Cronet et al). This compound is effective in treating conditions associated with insulin resistance.

Surprisingly a series of compounds has now been found which are highly potent PPAR α modulators.

Description of the invention

The present invention provides the S enantiomer of a compound of formula I



wherein R¹ represents 2,4-difluorophenyl or cyclohexyl as well as pharmaceutically acceptable salts, solvates, crystalline forms and prodrugs thereof.

The term "prodrug" as used in this specification includes derivatives of the carboxylic acid group which are converted in a mammal, particularly a human, into the carboxylic acid group or a salt or conjugate thereof. It should be understood that, whilst not being bound

by theory, it is believed that most of the activity associated with the prodrugs arises from the activity of the compound of formula I into which the prodrugs are converted. Prodrugs can be prepared by routine methodology well within the capabilities of someone skilled in the art. Various prodrugs of carboxy are known in the art. For examples of such prodrug derivatives, see:

- a) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985) and Methods in Enzymology. 42: 309-396, edited by K. Widder, *et al.* (Academic Press, 1985);
- b) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5 "Design and Application of Prodrugs", by H. Bundgaard p.113-191 (1991);
- c) H. Bundgaard, Advanced Drug Delivery Reviews, 8:1-38 (1992);
- d) H. Bundgaard, *et al.*, Journal of Pharmaceutical Sciences, 77:285 (1988); and
- e) N. Kakeya, *et al.*, Chem Pharm Bull, 32:692 (1984).

The above documents a to e are herein incorporated by reference.

In vivo cleavable esters are just one type of prodrug of the parent molecule. An *in vivo* hydrolysable (or cleavable) ester of a compound of the formula (I) that contains a carboxy group is, for example, a pharmaceutically acceptable ester which is hydrolysed in the human or animal body to produce the parent acid. Suitable pharmaceutically acceptable esters for carboxy include C₁₋₆alkoxymethyl esters, for example, methoxymethyl; C₁₋₆alkanoyloxymethyl esters, for example, pivaloyloxymethyl; phthalidyl esters; C₃₋₈cycloalkoxycarbonyloxyC₁₋₆alkyl esters, for example, 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolen-2-onylmethyl esters, for example, 5-methyl-1,3-dioxolen-2-onylmethyl; and C₁₋₆alkoxycarbonyloxyethyl esters, for example, 1-methoxycarbonyloxyethyl; and may be formed at any carboxy group in the compounds of this invention.

25

The compounds of formula I have activity as medicaments. In particular the compounds of formula I are highly potent agonists of PPAR α . In addition the compounds of formula I are also agonists of PPAR γ . The term agonists as used herein, includes partial agonists.

30 Specific compounds of the invention are:

(2S)-3-(4-{2-[(Cyclohexylmethyl)(heptyl)amino]-2-oxoethoxy}phenyl)-2-ethoxypropanoic acid ; and

(2S)-3-(4-{2-[(2,4-Difluorobenzyl)(heptyl)amino]-2-oxoethoxy}phenyl)-2-ethoxypropanoic acid;

5 and pharmaceutically acceptable salts, solvates and crystalline forms thereof.

In the present specification the expression "pharmaceutically acceptable salts" is intended to define but is not limited to base salts such as the alkali metal salts, alkaline earth metal salts, ammonium salts, salts with basic amino acids, and salts with organic amines.

10


It will also be understood that certain compounds of the present invention may exist in solvated, for example hydrated, as well as unsolvated forms. It is to be understood that the present invention encompasses all such solvated forms. Certain compounds of the present invention may exist as tautomers. It is to be understood that the present invention encompasses all such tautomers.

15

Methods of preparation

The compounds of the invention may be prepared as outlined below. However, the invention is not limited to these methods, the compounds may also be prepared as described for structurally related compounds in the prior art. The reactions can be carried out according to standard procedures or as described in the experimental section.

Compounds of formula I may be prepared by reacting the S enantiomer of a compound of formula II




25

in which R¹ is as previously defined and R² represents a protecting group for a carboxylic hydroxy group as described in the standard text "Protective Groups in Organic Synthesis", 2nd Edition (1991) by Greene and Wuts, with a de-protecting agent. The protecting group may also be a resin, such as Wang resin or 2-chlorotriyl chloride resin.


- 5 Protecting groups may be removed in accordance to techniques which are well known to those skilled in the art. One such protecting group is where R² represents a C₁₋₆alkoxy group or an arylalkoxy group eg benzyl, such that COR² represents an ester. Such esters can be reacted with a de-protecting reagent e.g. a hydrolysing agent, for example lithium hydroxide in a mixture of THF and water, at a temperature in the range of 0-100°C to give
- 10 compounds of formula I.

Compounds of formula II may be prepared by reacting the S enantiomer of a compound of formula III



15

in which R² is as previously defined with a compound of formula IV



20

in which R¹ is as previously defined in an inert solvent, for example dichloromethane, in the presence of a coupling agent, for example a carbodiimide, eg 1-(3-dimethylamino-propyl)-3-ethylcarbodiimide, and optionally in the presence of a catalyst, for example a basic catalyst, eg 4-dimethylaminopyridine, at a temperature in the range of -25°C to 25 150°C.

Compounds of formula III and IV may be prepared by methods described in the Examples or by analogous methods known to those skilled in the art.

Compounds of formula II and III are useful intermediates in the preparation of compounds
5 of formula I and are believed to be novel. Compounds of formula II and III are herein claimed as a further aspect of the present invention. The S-enantiomers of compounds of formula II and III are preferred.

The compounds of the invention may be isolated from their reaction mixtures using
10 conventional techniques.

Persons skilled in the art will appreciate that, in order to obtain compounds of the invention in an alternative and in some occasions, more convenient manner, the individual process steps mentioned hereinbefore may be performed in different order, and/or the individual
15 reactions may be performed at different stage in the overall route (i.e. chemical transformations may be performed upon different intermediates to those associated hereinbefore with a particular reaction).

The expression "inert solvent" refers to a solvent which does not react with the starting
20 materials, reagents, intermediates or products in a manner which adversely affects the yield of the desired product.

Pharmaceutical preparations

25 The compounds of the invention will normally be administered via the oral, parenteral, intravenous, intramuscular, subcutaneous or in other injectable ways, buccal, rectal, vaginal, transdermal and/or nasal route and/or via inhalation, in the form of pharmaceutical preparations comprising the active ingredient either as a free acid, or a pharmaceutical acceptable organic or inorganic base addition salt, in a pharmaceutically acceptable dosage

form. Depending upon the disorder and patient to be treated and the route of administration, the compositions may be administered at varying doses.

Suitable daily doses of the compounds of the invention in therapeutical treatment of
5 humans are about 0.0001-100 mg/kg body weight, preferably 0.001-10 mg/kg body weight.

Oral formulations are preferred particularly tablets or capsules which may be formulated by methods known to those skilled in the art to provide doses of the active compound in
10 the range of 0.5mg to 500mg for example 1 mg, 3 mg, 5 mg, 10 mg, 25mg, 50mg, 100mg and 250mg.

According to a further aspect of the invention there is thus provided a pharmaceutical formulation including any of the compounds of the invention, or pharmaceutically acceptable derivatives thereof, in admixture with pharmaceutically acceptable adjuvants,
15 diluents and/or carriers.

Pharmacological properties

The present compounds of formula (I) are useful for the prophylaxis and/or treatment of clinical conditions associated with inherent or induced reduced sensitivity to insulin
20 (insulin resistance) and associated metabolic disorders (also known as metabolic syndrome). These clinical conditions will include, but will not be limited to, general obesity, abdominal obesity, arterial hypertension, hyperinsulinaemia, hyperglycaemia, type 2 diabetes and the dyslipidaemia characteristically appearing with insulin resistance. This dyslipidaemia, also known as the atherogenic lipoprotein profile, is characterised by
25 moderately elevated non-esterified fatty acids, elevated very low density lipoprotein (VLDL) triglyceride rich particles, high Apo B levels, low high density lipoprotein (HDL) levels associated with low apoAI particle levels and high Apo B levels in the presence of small, dense, low density lipoproteins (LDL) particles, phenotype B.

The compounds of the present invention are expected to be useful in treating patients with combined or mixed hyperlipidemias or various degrees of hypertriglyceridemias and postprandial dyslipidemia with or without other manifestations of the metabolic syndrome.

5

Treatment with the present compounds is expected to lower the cardiovascular morbidity and mortality associated with atherosclerosis due to their antidyslipidaemic as well as antiinflammatory properties. The cardiovascular disease conditions include macroangiopathies of various internal organs causing myocardial infarction, congestive heart failure, cerebrovascular disease and peripheral arterial insufficiency of the lower extremities. Because of their insulin sensitizing effect the compounds of formula I are also expected to prevent or delay the development of type 2 diabetes from the metabolic syndrome and diabetes of pregnancy. Therefore the development of long-term complications associated with chronic hyperglycaemia in diabetes mellitus such as the micro-angiopathies causing renal disease, retinal damage and peripheral vascular disease of the lower limbs are expected to be delayed. Furthermore the compounds may be useful in treatment of various conditions outside the cardiovascular system whether or not associated with insulin resistance, like polycystic ovarian syndrome, obesity, cancer and states of inflammatory disease including neurodegenerative disorders such as mild cognitive impairment, Alzheimer's disease, Parkinson's disease and multiple sclerosis.

10

15

20

The compounds of the present invention are expected to be useful in controlling glucose levels in patients suffering from type 2 diabetes.

25

The present invention provides a method of treating or preventing dyslipidemias, the insulin resistance syndrome and/or metabolic disorders (as defined above) comprising the administration of a compound of formula I to a mammal (particularly a human) in need thereof.

30

The present invention provides a method of treating or preventing type 2 diabetes comprising the administration of an effective amount of a compound of formula I to a mammal (particularly a human) in need thereof.

In a further aspect the present invention provides the use of a compound of formula I as a medicament.

5 In a further aspect the present invention provides the use of a compound of formula I in the manufacture of a medicament for the treatment of insulin resistance and/or metabolic disorders.

Combination Therapy

10 The compounds of the invention may be combined with other therapeutic agents that are useful in the treatment of disorders associated with the development and progress of atherosclerosis such as hypertension, hyperlipidaemias, dyslipidaemias, diabetes and obesity. The compounds of the invention may be combined with another therapeutic agent
15 that decreases the ratio of LDL:HDL or an agent that causes a decrease in circulating levels of LDL-cholesterol. In patients with diabetes mellitus the compounds of the invention may also be combined with therapeutic agents used to treat complications related to micro-angiopathies.

20 The compounds of the invention may be used alongside other therapies for the treatment of metabolic syndrome or type 2 diabetes and its associated complications, these include biguanide drugs, for example metformin, phenformin and buformin, insulin (synthetic insulin analogues, amylin) and oral antihyperglycemics (these are divided into prandial glucose regulators and alpha-glucosidase inhibitors). An example of an alpha-glucosidase
25 inhibitor is acarbose or voglibose or miglitol. An example of a prandial glucose regulator is repaglinide or nateglinide.

In another aspect of the invention, the compound of formula I, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, may be administered in
30 association with another PPAR modulating agent. PPAR modulating agents include but are not limited to a PPAR alpha and/or gamma agonist, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof. Suitable PPAR alpha and/or gamma

agonists, pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof are well known in the art. These include the compounds described in WO 01/12187, WO 01/12612, WO 99/62870, WO 99/62872, WO 99/62871, WO 98/57941, WO 01/40170, J Med Chem, 1996, 39, 665, Expert Opinion on Therapeutic Patents, 10 (5), 623-634 (in particular the compounds described in the patent applications listed on page 634) and J Med Chem, 2000, 43, 527 which are all incorporated herein by reference.

Particularly a PPAR alpha and/or gamma agonist refers to NN622/Ragaglitazar, BMS 298585, WY-14643, clofibrate, fenofibrate, bezafibrate, gemfibrozil and ciprofibrate; GW 9578, ciglitazone, troglitazone, pioglitazone, rosiglitazone, eglitazone, proglitazone, BRL-49634, KRP-297, JTT-501, SB 213068, GW 1929, GW 7845, GW 0207, L-796449, L-165041 and GW 2433. Particularly a PPAR alpha and/or gamma agonist refers to (S)-2-ethoxy-3-[4-(2-{4-methanesulphonyloxyphenyl}ethoxy)-phenyl]propanoic acid and pharmaceutically acceptable salts thereof.

In addition the combination of the invention may be used in conjunction with a sulfonylurea for example: glimepiride, glibenclamide (glyburide), gliclazide, glipizide, gliquidone, chloropropamide, tolbutamide, acetohexamide, glycopyramide, carbutamide, glibonuride, glisoxepid, glybuthiazole, glibuzole, glyhexamide, glymidine, glypinamide, phenbutamide, tolcylamide and tolazamide. Preferably the sulfonylurea is glimepiride or glibenclamide (glyburide). More preferably the sulfonylurea is glimepiride. Therefore the present invention includes administration of a compound of the present invention in conjunction with one, two or more existing therapies described in this paragraph. The doses of the other existing therapies for the treatment of type 2 diabetes and its associated complications will be those known in the art and approved for use by regulatory bodies for example the FDA and may be found in the Orange Book published by the FDA. Alternatively smaller doses may be used as a result of the benefits derived from the combination.

The present invention also includes a compound of the present invention in combination with a cholesterol-lowering agent. The cholesterol-lowering agents referred to in this application include but are not limited to inhibitors of HMG-CoA reductase (3-hydroxy-3-methylglutaryl coenzyme A reductase). Suitably the HMG-CoA reductase inhibitor is a

statin selected from the group consisting of atorvastatin, bervastatin, cerivastatin, dalvastatin, fluvastatin, itavastatin, lovastatin, mevastatin, nicostatin, nivastatin, pravastatin and simvastatin, or a pharmaceutically acceptable salt, especially sodium or calcium, or a solvate thereof, or a solvate of such a salt. A particular statin is atorvastatin, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof. A more particular statin is atorvastatin calcium salt. A particularly preferred statin is, however, a compound with the chemical name (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)-amino]-pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid, [also known as (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[N-methyl-N-(methylsulfonyl)-amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt. The compound (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl-(methylsulfonyl)-amino]-pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid, and its calcium and sodium salts are disclosed in European Patent Application, Publication No. EP-A-0521471, and in Bioorganic and Medicinal Chemistry, (1997), 5(2), 437-444. This latter statin is now known under its generic name rosuvastatin.

In the present application, the term "cholesterol-lowering agent" also includes chemical modifications of the HMG-CoA reductase inhibitors, such as esters, prodrugs and metabolites, whether active or inactive.

The present invention also includes a compound of the present invention in combination with an inhibitor of the ileal bile acid transport system (IBAT inhibitor).

Suitable compounds possessing IBAT inhibitory activity have been described, see for instance the compounds described in WO 93/16055, WO 94/18183, WO 94/18184, WO 96/05188, WO 96/08484, WO 96/16051, WO 97/33882, WO 98/07449, WO 98/03818, WO 98/38182, WO 99/32478, WO 99/35135, WO 98/40375, WO 99/35153, WO 99/64409, WO 99/64410, WO 00/01687, WO 00/47568, WO 00/61568, WO 00/62810, WO 01/68906, DE 19825804, WO 00/38725, WO 00/38726, WO 00/38727, WO 00/38728, WO 00/38729, WO 01/68906, WO 01/66533, WO 02/32428, WO 02/50051, EP 864 582, EP489423, EP549967, EP573848, EP624593, EP624594, EP624595 and

EP624596 and the contents of these patent applications are incorporated herein by reference.

Particular classes of IBAT inhibitors suitable for use in the present invention are

s benzothiepines, and the compounds described in the claims, particularly claim 1, of WO 00/01687, WO 96/08484 and WO 97/33882 are incorporated herein by reference. Other suitable classes of IBAT inhibitors are the 1,2-benzothiazepines, 1,4-benzothiazepines and 1,5-benzothiazepines. A further suitable class of IBAT inhibitors is the 1,2,5-benzothiadiazepines.

10

One particular suitable compound possessing IBAT inhibitory activity is (3*R*,5*R*)-3-butyl-3-ethyl-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl β-D-glucopyranosiduronic acid (EP 864 582). Other suitable IBAT inhibitors include one of:

15 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)-1'-phenyl-1'-[*N*'-(carboxymethyl)carbamoyl]methyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)-α-[*N*'-(carboxymethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

20 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)-1'-phenyl-1'-[*N*'-(2-sulphoethyl)carbamoyl]methyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{(R)-1'-phenyl-1'-[*N*'-(2-sulphoethyl)carbamoyl]methyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

25 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)-α-[*N*'-(2-sulphoethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{(R)-α-[*N*'-(2-sulphoethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(*N*-{(R)-α-[*N*'-(2-

30 carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- α -[N'-(2-carboxyethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N-{(R)- α -[N'-(5-carboxypentyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- α -[N'-(2-carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{ α -[N'-(2-sulphoethyl)carbamoyl]-2-fluorobenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N-{(R)- α -[N'-(R)-(2-hydroxy-1-carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- α -[N'-(R)-(2-hydroxy-1-carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-{N-[(R)- α -{N'-(R)-1-[N''-(R)-(2-hydroxy-1-carboxyethyl)carbamoyl]-2-hydroxyethyl}carbamoyl]benzyl}carbamoylmethoxy}-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N-{ α -[N'-(carboxymethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N-{ α -[N'-((ethoxy)(methyl)phosphoryl-methyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-{N-[(R)- α -{N'-(2-[(hydroxy)(methyl)phosphoryl]ethyl}carbamoyl]benzyl}carbamoylmethoxy}-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- α -[N'-(2-methylthio-1-carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-{N-[{(R)- α -(N'-{2-[(methyl)(ethyl)phosphoryl]ethyl}carbamoyl)-4-hydroxybenzyl]carbamoylmethoxy}-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-{N-[{(R)- α -(N'-{2-[(methyl)(hydroxy)phosphoryl]ethyl}carbamoyl)-4-hydroxybenzyl]carbamoylmethoxy}-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-{N-[{(R)- α -[(R)-N'-(2-methylsulphinyl-1-carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy}-2,3,4,5-tetrahydro-1,5-benzothiazepine;

10 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methoxy-8-[N-{(R)- α -[N'-(2-sulphoethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy]-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-{N-[{(R)- α -[N-((R)-1-carboxy-2-methylthio-ethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy}-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

15 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-{N-[{(R)- α -[N-((S)-1-carboxy-2-(R)-hydroxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy}-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-{N-[{(R)- α -[N-((S)-1-carboxy-2-methylpropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy}-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

20 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-{N-[{(R)- α -[N-((S)-1-carboxybutyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy}-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-{N-[{(R)- α -[N-((S)-1-carboxypropyl)carbamoyl]benzyl}carbamoylmethoxy}-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

25 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-{N-[{(R)- α -[N-((S)-1-carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy}-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-{N-[{(R)- α -[N-((S)-1-carboxy-2-(R)-hydroxypropyl)carbamoyl]benzyl}carbamoylmethoxy}-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

30 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-{N-[{(R)- α -[N-((S)-1-carboxy-2-(R)-hydroxypropyl)carbamoyl]benzyl}carbamoylmethoxy}-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- α -[N-(2-sulphoethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- α -[N-((S)-1-carboxyethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- α -[N-((R)-1-carboxy-2-methylthioethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- α -[N-((S)-1-[N-((S)-2-hydroxy-1-carboxyethyl)carbamoyl]propyl}carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- α -[N-((S)-1-carboxy-2-methylpropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

15 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- α -[N-((S)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-[N-(R/S)- α -{N-[1-(R)-2-(S)-1-hydroxy-1-(3,4-dihydroxyphenyl)prop-2-yl]carbamoyl}-4-hydroxybenzyl}carbamoylmethoxy]-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

20 2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- α -[N-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine; and

1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- α -[N-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

25 or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

According to an additional further aspect of the present invention there is provided a combination treatment comprising the administration of an effective amount of a compound of the formula I, or a pharmaceutically acceptable salt, solvate, solvate of such a

salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier, with the simultaneous, sequential or separate administration one or more of the following agents selected from:

- a CETP (cholesterol ester transfer protein) inhibitor, for example those referenced and described in WO 00/38725 page 7 line 22 - page 10, line 17 which are incorporated herein by reference;
- 5 a cholesterol absorption antagonist for example azetidinones such as SCH 58235 and those described in US 5,767,115 which are incorporated herein by reference;
- 10 a MTP (microsomal transfer protein) inhibitor for example those described in Science, 282, 751-54, 1998 which are incorporated herein by reference;
- 15 a nicotinic acid derivative, including slow release and combination products, for example, nicotinic acid (niacin), acipimox and nericinol;
- a phytosterol compound for example stanols;
- probucol;
- 15 an anti-obesity compound for example orlistat (EP 129,748) and sibutramine (GB 2,184,122 and US 4,929,629);
- an antihypertensive compound for example an angiotensin converting enzyme (ACE) inhibitor, an angiotensin II receptor antagonist, an adrenergic blocker, an alpha adrenergic blocker, a beta adrenergic blocker, a mixed alpha/beta adrenergic blocker,
- 20 an adrenergic stimulant, calcium channel blocker, an AT-1 blocker, a saluretic, a diuretic or a vasodilator;
- a CB1 antagonist or inverse agonist for example as described in WO01/70700 and EP 65635 ;
- 25 a Melanin concentrating hormone (MCH) antagonist;
- a PDK inhibitor; or
- modulators of nuclear receptors for example LXR, FXR, RXR and RORalpha;
- or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier to a warm-blooded animal, such as man in need of such therapeutic treatment.

30

Particular ACE inhibitors or pharmaceutically acceptable salts, solvates, solvate of such salts or a prodrugs thereof, including active metabolites, which can be used in combination

with a compound of formula I include but are not limited to, the following compounds: alacepril, alatriopril, altiopril calcium, ancovenin, benazepril, benazepril hydrochloride, benazeprilat, benzoylcaptopril, captopril, captopril-cysteine, captopril-glutathione, ceranapril, ceranopril, ceronapril, cilazapril, cilazaprilat, delapril, delapril-diacid, enalapril, 5 enalaprilat, enapril, epicaptopril, foroxymithine, fosfenopril, fosenopril, fosenopril sodium, fosinopril, fosinopril sodium, fosinoprilat, fosinoprilic acid, glycopril, hemorphin-4, idrapril, imidapril, indolapril, indolaprilat, libenzapril, lisinopril, lyciumin A, lyciumin B, mixanpril, moexipril, moexiprilat, moveltipril, muracein A, muracein B, muracein C, pentopril, perindopril, perindoprilat, pivalopril, pivopril, quinapril, quinapril hydrochloride, 10 quinaprilat, ramipril, ramiprilat, spirapril, spirapril hydrochloride, spiraprilat, spiropril, spiropril hydrochloride, temocapril, temocapril hydrochloride, tetrootide, trandolapril, trandolaprilat, utibapril, zabicapril, zabicaprilat, zofenopril and zofenoprilat. Preferred ACE 15 inhibitors for use in the present invention are ramipril, ramiprilat, lisinopril, enalapril and enalaprilat. More preferred ACE inhibitors for uses in the present invention are ramipril and ramiprilat.

Preferred angiotensin II antagonists, pharmaceutically acceptable salts, solvates, solvate of such salts or a prodrugs thereof for use in combination with a compound of formula I include, but are not limited to, compounds: candesartan, candesartan cilexetil, losartan, 20 valsartan, irbesartan, tasosartan, telmisartan and eprosartan. Particularly preferred angiotensin II antagonists or pharmaceutically acceptable derivatives thereof for use in the present invention are candesartan and candesartan cilexetil.

Therefore in an additional feature of the invention, there is provided a method for the treatment of type 2 diabetes and its associated complications in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof in simultaneous, sequential or separate administration with an effective amount of one the other compounds described in this 25 combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

Therefore in an additional feature of the invention, there is provided a method of treating hyperlipidemic conditions in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a

5 compound of formula I, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof in simultaneous, sequential or separate administration with an effective amount of one the other compounds described in this combination section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

10 According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula I, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and one of the other compounds described in this combination section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in association with a pharmaceutically acceptable

15 diluent or carrier.

According to a further aspect of the present invention there is provided a kit comprising a compound of formula I, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and one of the other compounds described in this combination

20 section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

According to a further aspect of the present invention there is provided a kit comprising:

a) a compound of formula I, or a pharmaceutically acceptable salt, solvate, solvate of such

25 a salt or a prodrug thereof, in a first unit dosage form;

b) one of the other compounds described in this combination section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof; in a second unit dosage form; and

c) container means for containing said first and second dosage forms.

30 According to a further aspect of the present invention there is provided a kit comprising:

- a) a compound of formula I, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, together with a pharmaceutically acceptable diluent or carrier, in a first unit dosage form;
- b) one of the other compounds described in this combination section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in a second unit dosage form; and
- c) container means for containing said first and second dosage forms.

According to another feature of the invention there is provided the use of a compound of the formula I, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment of metabolic syndrome or type 2 diabetes and its associated complications in a warm-blooded animal, such as man.

According to another feature of the invention there is provided the use of a compound of the formula I, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment of hyperlipidaemic conditions in a warm-blooded animal, such as man.

According to a further aspect of the present invention there is provided a combination treatment comprising the administration of an effective amount of a compound of the formula I, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier, with the simultaneous, sequential or separate administration of an effective amount of one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier to a warm-blooded animal, such as man in need of such therapeutic treatment.

Examples

¹H NMR and ¹³C NMR measurements were performed on a Varian Mercury 300 or
5 Varian UNITY plus 400, 500 or 600 spectrometers, operating at ¹H frequencies of 300,
400, 500 and 600 MHz, respectively, and at ¹³C frequencies of 75, 100, 125 and 150 MHz,
respectively. Measurements were made on the delta scale (δ).

Unless otherwise stated, chemical shifts are given in ppm with the solvent as
internal standard.

10

Abbreviations

DMSO	dimethyl sulfoxide
THF	tetrahydrofuran
DMAP	dimethylaminopyridine
t	triplet
s	singlet
d	doublet
q	quartet
m	multiplet
bs	broad singlet

Example 1

(2S)-3-(4-{2-[(Cyclohexylmethyl)(heptyl)amino]-2-oxoethoxy}phenyl)-2-ethoxypopropanoic acid

25 (i) Ethyl (2S)-3-{4-[2-(benzyloxy)-2-oxoethoxy]phenyl}-2-ethoxypropanoate

To a solution of ethyl (2S)-2-ethoxy-3-(4-hydroxyphenyl)propanoate (23.8 g, 100 mmol, prepared as described in WO99/62872) in acetonitrile (200 mL) was added anhydrous potassium carbonate (31.9 g, 231 mmol) followed by benzyl bromoacetate (17.4 mL, 110 mmol) and the reaction mixture was refluxed overnight. The reaction mixture was allowed to cool to room temperature, insoluble salts were filtered off and the solution was concentrated *in vacuo*. The residue was taken up in ethyl acetate (300 mL), and the organic phase was

washed with aqueous NaHCO₃ (3 x 100 mL) and brine (100 mL), dried over anhydrous MgSO₄, and concentrated *in vacuo*. Purification on silica gel with methylene chloride as the eluent and collection of pure fractions yielded 22.4 g (58%) of a yellow oil.

5 ¹H NMR (400 MHz, CDCl₃): δ 1.16 (t, 3H), 1.22 (t, 3H), 2.93–2.97 (m, 2H), 3.35 (m, 1H),
3.60 (m, 1H), 3.97 (m, 1H), 4.16 (q, 2H), 4.64 (s, 2H), 5.23 (s, 2H), 6.82 (d, 2H), 7.15 (d,
2H), 7.32–7.39 (m, 5H).

10 ¹³C NMR (100 MHz, CDCl₃): δ 14.3, 15.2, 38.6, 60.9, 65.6, 66.3, 67.0, 80.4, 114.6, 128.5,
128.6, 128.7, 130.6, 135.3, 156.7, 169.0, 172.6.

(ii) {4-[(2S)-2,3-Diethoxy-3-oxopropyl]phenoxy}acetic acid

15 To a solution of ethyl (2S)-3-{4-[2-(benzyloxy)-2-oxoethoxy]phenyl}-2-ethoxypropanoate
(22.33 g, 57.8 mmol) in freshly distilled THF (290 mL) was added Pd/C (10%, 3.1 g) and the
reaction mixture was hydrogenated under atmospheric pressure at room temperature
overnight. The mixture was filtered through a plug of Celite and the filtrate was concentrated
in vacuo to afford 16.6 g (97%) of a light yellow oil.

20 ¹H NMR (400 MHz, CDCl₃): δ 1.15 (t, 3H), 1.21 (t, 3H), 2.93–2.98 (m, 2H), 3.35 (m, 1H),
3.60 (m, 1H), 3.97 (m, 1H), 4.16 (q, 2H), 4.65 (s, 2H), 6.84 (d, 2H), 7.17 (d, 2H), 8.48 (bs,
1H)

25 ¹³C NMR (100 MHz, CDCl₃): δ 14.3, 15.1, 38.5, 61.0, 65.1, 66.4, 80.3, 114.6, 130.7, 130.9,
156.4, 172.7, 173.7

(iii) N-(Cyclohexylmethyl)heptanamide

30 To a solution of aminomethylcyclohexane (0.34 g, 3.0 mmol) in methylene chloride (30 mL)
was added heptanoic acid (0.39 g, 3 mmol) and DMAP (0.37 g, 3.0 mmol) followed by 1-

ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.57 g, 3.0 mmol) and the reaction mixture was stirred at room temperature overnight. The mixture was diluted with methylene chloride (100 mL), and the organic phase was washed with 5% HCl (3x75 mL), aqueous NaHCO₃ (75 mL) and brine (75 mL), and dried over Na₂SO₄. Concentration *in vacuo* afforded 0.62 g (92%) of an oil, which then crystallised.

¹H NMR (400 MHz, CDCl₃): δ 0.84–0.98 (m, 5H), 1.08–1.36 (m, 8H), 1.44 (m, 1H), 1.56–1.78 (m, 8H), 2.16 (t, 2H), 3.09 (t, 2H), 5.45 (bs, 1H).

¹⁰ ¹³C NMR (100 MHz, CDCl₃): δ 14.1, 22.7, 26.0, 26.6, 29.1, 31.0, 31.7, 37.1, 38.1, 45.8, 173.2.

(iv) N-(Cyclohexylmethyl)-N-heptylamine hydrochloride

¹⁵ *N*-(Cyclohexylmethyl)heptanamide (0.58 g, 2.6 mmol) was dried once by azeotropic distillation with toluene, taken up in freshly distilled THF (23 mL) and cooled on an icebath under an argon atmosphere. Borane, (3.2 mL of a 2M solution of the methylsulfide complex in diethylether) was added and the icebath was removed after 15 minutes. The reaction mixture was refluxed for four hours and was then allowed to cool to room temperature. 1.2 mL of 10% HCl was carefully added and the mixture was left with stirring overnight. Concentration *in vacuo* followed by the addition of ice cold THF (*ca.* 15 mL) gave a white precipitate. Water (*ca.* 3 mL) was added followed by toluene (*ca.* 10 mL) and the mixture was concentrated *in vacuo*. Ice cold THF (*ca.* 15 ml) was added to the residue and the resulting precipitate was filtered off and dried *in vacuo* to give 2.96 g of crude product as a white salt.

²⁰ This material was used in the subsequent reaction step without any further purification.

¹H NMR (400 MHz, CD₃OD): δ 0.87–0.98 (m, 3H), 0.97–1.11 (m, 2H), 1.15–1.45 (m, 11H), 1.65–1.86 (m, 8H), 2.84 (d, 2H), 2.93–3.01(m, 2H).

³⁰ ¹³C NMR (100 MHz, CD₃OD): δ 14.3, 23.6, 26.6, 27.0, 27.1, 27.6, 29.9, 31.5, 32.7, 36.4, 55.0.

(v) Ethyl (2S)-3-(4-{2-[cyclohexylmethyl](heptyl)amino]-2-oxoethoxy}phenyl)-2-ethoxypropanoate

To a solution of {4-[(2S)-2,3-diethoxy-3-oxopropyl]phenoxy}acetic acid (0.108 g, 0.36 mmol) in methylene chloride (3.6 mL) were added *N*-(cyclohexylmethyl)-*N*-heptylamine hydrochloride (0.090 g, 0.36 mmol) and DMAP (0.098 g, 0.80 mmol) followed by 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.070 g, 0.36 mmol) and the reaction mixture was stirred at room temperature overnight. The mixture was diluted with methylene chloride (25 mL) and the organic phase was washed with 5% HCl (3 x 25 mL), aqueous NaHCO₃ (25 mL) and brine (25 mL), dried over Na₂SO₄, and concentrated *in vacuo*. Purification on a prepacked column of silica gel (Isolute® SPE Column, 5 g Si/25 mL) with methanol (0–1% gradient) in methylene chloride as the eluent yielded 0.103 g (58%) of a colourless oil.

¹⁵ ¹H NMR (400 MHz, CDCl₃): δ 0.83–0.97 (m, 5H), 1.11–1.33 (m, 17H), 1.45–1.80 (m, 8H), 2.88–3.00 (m, 2H), 3.14 and 3.19 (2d, 2H, rotamers), 3.24–3.39 (m, 3H), 3.58 (m, 1H), 3.95 (m, 1H), 4.15 (q, 2H), 4.64 and 4.66 (2s, 2H, rotamers), 6.84 and 6.84 (2d, 2H, rotamers), 7.14 (d, 2H)

²⁰ ¹³C NMR (100 MHz, CDCl₃): δ 14.2, 14.3, 15.2, 22.7, 26.0, 26.0, 26.5, 26.5, 27.0, 27.0, 27.2, 28.9, 29.1, 31.0, 31.2, 31.9, 36.1, 37.3, 38.6, 46.4, 48.0, 51.7, 53.3, 60.9, 66.3, 67.5, 67.7, 80.4, 114.6, 114.7, 130.2, 130.5, 157.1, 157.1, 167.8, 167.9, 172.6 (The number of peaks is larger than the number of carbon atoms due to rotamers.)

²⁵ (vi) (2S)-3-(4-{2-[Cyclohexylmethyl](heptyl)amino}-2-oxoethoxy}phenyl)-2-ethoxypropanoic acid

To a solution of ethyl (2S)-3-(4-{2-[cyclohexylmethyl](heptyl)amino]-2-oxoethoxy}phenyl)-2-ethoxy-propanoate (0.031 g, 0.057 mmol) in THF (2.0 mL) were added water (2.0 mL) and lithium hydroxide (0.006 g, 0.26 mmol), and the reaction mixture was stirred at room temperature overnight. The mixture was acidified with 2M HCl and extracted with ethyl

acetate (4 x 25 mL). The combined organic phase was washed with brine (25 mL), dried over Na₂SO₄, and concentrated *in vacuo* to afford 0.027 g (93%) of a colourless oil.

¹H NMR (400 MHz, CDCl₃): δ 0.82–0.99 (m, 5H), 1.10–1.35 (m, 14H), 1.46–1.82 (m, 8H),
5 2.94 (m, 1H), 3.05 (m, 1H), 3.15 and 3.21 (2d, 2H, rotamers), 3.25–3.46 (m, 3H), 3.61 (m, 1H), 4.02 (m, 1H), 4.66 and 4.68 (2s, 2H, rotamers), 6.85 (d, 2H), 7.16 (d, 2H), 7.77 (bs, 1H).

¹³C NMR (100 MHz, CDCl₃): δ 14.2, 15.1, 22.7, 26.0, 26.0, 26.4, 26.5, 27.0, 27.0, 27.2, 28.9,
10 29.1, 31.0, 31.2, 31.9, 36.1, 37.2, 38.0, 46.6, 48.0, 51.8, 53.4, 66.8, 67.3, 67.5, 79.9, 114.7,
114.8, 129.9, 130.6, 157.1, 157.2, 168.2, 168.3, 175.2. (The number of peaks is larger than
the number of carbon atoms due to rotamers.)

Example 2

15 (2S)-3-(4-{2-[*(2,4-Difluorobenzyl)(heptyl)amino*]-2-oxoethoxy}phenyl)-2-ethoxypropanoic
acid

(i) N-(2,4-Difluorobenzyl)heptanamide

20 To a solution of 2,4-difluorobenzylamine (0.43 g, 3.0 mmol) in methylene chloride (30 mL)
were added heptanoic acid (0.39 g, 3.0 mmol) and DMAP (0.37 g, 3.0 mmol) followed by 1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.58 g, 3.0 mmol) and the
reaction mixture was stirred at room temperature overnight. The mixture was diluted with
methylene chloride (100 mL), and the organic phase was washed with 5% HCl (3x75 mL),
25 aqueous NaHCO₃ (75 mL) and brine (75 mL), and dried over Na₂SO₄. Concentration *in vacuo*
afforded 0.63 g (82%) of a yellow oil.

¹H NMR (400 MHz, CDCl₃): δ 0.83–0.91 (m, 3H), 1.22–1.35 (m, 6H), 1.56–1.68 (m, 2H),
2.19 (t, 2H), 4.43 (d, 2H), 5.80 (bs, 1H), 6.75–6.88 (m, 2H), 7.33 (m, 1H).

30

¹³C NMR (100 MHz, CDCl₃): δ 14.1, 22.6, 25.7, 29.0, 31.6, 36.8, 37.1, 104.0 (t), 111.5 (dd),
131.5 (dd), 173.2. (Non-protonated carbons not reported.).

(ii) N-(2,4-Difluorobenzyl)-N-heptylamine hydrochloride

5 *N*-(2,4-Difluorobenzyl)heptanamide (0.55 g, 2.2 mmol) was dried once by azeotropic distillation with toluene, taken up in freshly distilled THF (19 mL) and cooled on an icebath under an argon atmosphere. Borane, (2.7 mL of a 2M solution of the dimethyl sulfide complex in diethyl ether) was added and the icebath was removed after 15 minutes. The reaction mixture was refluxed for four hours and was then allowed to cool to room temperature. 1.0 mL of 10% HCl was carefully added and the mixture was left with stirring overnight. Concentration *in vacuo* followed by the addition of ice cold THF (*ca.* 15 mL) gave a precipitate, which was filtered off and dried *in vacuo* to afford 0.81 g of crude product as an off-white salt. This material was used in the subsequent reaction step without any further purification.

15 ¹H NMR (400 MHz, CD₃OD): δ 0.88–0.95 (m, 3H), 1.27–1.45 (m, 8H), 1.66–1.79 (m, 2H), 3.03–3.10 (m, 2H), 4.27 (s, 2H), 7.06–7.17 (m, 2H), 7.62 (m, 1H).

13C NMR (100 MHz, CD₃OD): δ 14.3, 23.6, 27.1, 27.5, 29.8, 32.7, 45.0 (d), 48.9, 105.4 (t), 113.3 (dd), 134.8 (dd). (Non-protonated carbons not reported.)

20 (iii) Ethyl (2S)-3-(4-{[2,4-difluorobenzyl](heptyl)amino}-2-oxoethoxy)phenyl)-2-ethoxypopropanoate

To a solution of {4-[*(2S)*-2,3-diethoxy-3-oxopropyl]phenoxy}acetic acid (0.104 g, 0.35 mmol) in methylene chloride (3.5 mL) was added *N*-(2,4-difluorobenzyl)-*N*-heptylamine hydrochloride (0.098 g, 0.35 mmol) and DMAP (0.094 g, 0.77 mmol) followed by 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.067 g, 0.35 mmol) and the reaction mixture was stirred at room temperature overnight. The mixture was diluted with methylene chloride (50 mL), and the organic phase was washed with 5% HCl (3 x 25 mL), aqueous NaHCO₃ (25 mL) and brine (25 mL), dried over Na₂SO₄, and concentrated *in vacuo*. Purification on a prepacked column of silica gel (Isolute® SPE Column, 5g Si/25 mL) with

methanol (0–1% gradient) in methylene chloride as the eluent afforded 0.066 g (36%) of a colourless oil.

5 ¹H NMR (400 MHz, CDCl₃): δ 0.81–0.90 (m, 3H), 1.15 (t, 3H), 1.17–1.31 (m, 11H), 1.43–1.65 (m, 2H), 2.89–3.00 (m, 2H), 3.24–3.39 (m, 3H), 3.59 (m, 1H), 3.96 (m, 1H), 4.15 (q, 2H), 4.60 (s, 2H), 4.69 and 4.70 (2s, 2H, rotamers), 6.73–6.88 (m, 4H), 7.08–7.22 and 7.22–7.31 (2m, 3H, rotamers).

10 ¹³C NMR (100 MHz, CDCl₃): δ 14.1, 14.3, 15.1, 22.6, 26.9, 27.1, 28.7, 29.0, 31.8, 38.5, 41.5, 44.3, 46.1, 47.2, 60.9, 66.3, 67.5, 68.1, 80.3, 103.6 (t), 104.2 (t), 111.6 (dd), 114.4, 114.6, 119.8 (dd), 120.3 (dd), 129.6 (dd), 130.4, 130.6, 131.7 (dd), 156.7, 156.9, 168.2, 168.3, 172.5 (The number of peaks is larger than the number of carbon atoms due to rotamers. Fluorinated carbons not reported.)

15 (iv) (2S)-3-(4-{2-[(2,4-Difluorobenzyl)(heptyl)amino]-2-oxoethoxy}phenyl)-2-ethoxypropanoic acid

20 To a solution of ethyl (2S)-3-(4-{2-[(2,4-difluorobenzyl)(heptyl)amino]-2-oxoethoxy}phenyl)-2-ethoxypropanoate (0.047 g, 0.090 mmol) in THF (2.0 mL) was added water (2.0 mL) and lithium hydroxide (0.010 mg, 0.42 mmol) and the reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated *in vacuo*, acidified with 2M HCl, and extracted with ethyl acetate (4 x 25 mL). The combined organic phase was washed with brine (25 mL), dried over Na₂SO₄, and concentrated *in vacuo* to afford 0.044 g (89%) of a colourless oil.

25 ¹H NMR (400 MHz, CDCl₃): δ 0.83–0.93 (m, 3H), 1.17 (t, 3H), 1.20–1.35 (m, 8H), 1.45–1.67 (m, 2H), 2.90–3.14 (m, 2H), 3.26–3.35 (m, 2H), 3.42 (m, 1H), 3.63 (m, 1H), 4.04 (m, 1H), 4.63 (s, 2H), 4.74 (s, 2H), 6.75–6.90 (m, 4H), 7.11–7.22 and 7.25–7.35 (2m, 3H, rotamers), 9.13 (bs, 1H).

30 ¹³C NMR (100 MHz, CDCl₃): δ 14.1, 15.1, 22.6, 26.9, 27.1, 28.6, 29.0, 31.8, 38.0, 41.6, 44.3, 46.2, 47.3, 66.8, 67.3, 68.0, 79.8, 103.7 (t), 104.3 (t), 104.3, 111.7 (dd), 114.6, 114.7, 119.7 (dd), 120.1 (dd), 129.7 (m), 130.1, 130.7, 131.8 (dd), 156.8, 157.0, 168.6, 168.7, 175.6 (The

number of peaks is larger than the number of carbon atoms due to rotamers. Fluorinated carbons not reported.)

BIOLOGICAL ACTIVITY

5 FORMULATIONS

Compounds were dissolved in DMSO to obtain 16 mM stock solutions. Before assays, stock solutions were further diluted in DMSO and culture media.

GENERAL CHEMICALS AND REAGENTS

10 Luciferase assay reagent was purchased from Packard, USA. Restriction Enzymes were from Boehringer and Vent polymerase from New England Biolabs.

CELL LINES AND CELL CULTURE CONDITIONS

U2-OS, (Osteogenic sarcoma, Human) was purchased from ATCC, USA. Cells were expanded and refrozen in batches from passage number six. Cells were cultured in Dulbecco's modified Eagle medium (DMEM) with 25 mM glucose, 2 mM glutamine or 4 mM L-alanyl-L-glutamine, 10% fetal calf serum, at 5% CO₂. Phosphate buffered saline (PBS) without addition of calcium or magnesium was used. All cell culture reagents were 15 from Gibco (USA) and 96-well cell culture plates were purchased from Wallach.

PLASMID CONSTRUCTS FOR HETEROLOGOUS EXPRESSION

20 Standard recombinant DNA techniques were carried out as described by Ausubel (7). The Luciferase reporter vector, pGL5UAS (clone consists of five copies of the GAL4 DNA binding sequence, 5'-CGACGGAGTACTGTCCTCCGAGCT-3', cloned into the SacI/XhoI sites of pGL3-Promoter (Promega). The SacI/XhoI fragment carrying the UAS sites was constructed using annealed overlapping oligonucleotides.

25

Expression vectors used are based upon pSG5 (Stratagene). All vectors contain an EcoRI/NheI fragment encoding the DNA binding domain of GAL4 (encoding amino acid positions 1-145 of database accession number P04386) followed by an in-frame fusion to a fragment encoding the nuclear localisation sequence from T antigen of Polyoma Virus.

The nuclear localisation sequence was constructed using annealed overlapping oligonucleotides creating NheI/KpnI sticky ends (5'-CTAGCGCTCCTAGAAGAACGCAAGGTTGGTAC-3'). The ligand binding domains from human and mouse PPAR α and human and mouse PPAR γ were PCR amplified as KpnI/BamHI fragments and cloned in frame to the GAL4 DNA binding domain and the nuclear localisation sequence. The sequence of all plasmid constructs used were confirmed by sequencing. The following expression vectors were used for transient transfections:

vector	encoded PPAR subtype	sequence reference ¹
pSGGALhPPa	human PPAR α	S74349, nt 625-1530
pSGGALmPPa	murine PPAR α	X57638, nt 668-1573
pSGGALhPPg	human PPAR γ	U63415, nt 613-1518
pSGGALmPPg	murine PPAR γ	U09138, nt 652-1577

10

¹ refers to nucleotide positions of data base entry used to express the ligand binding domain.

TRANSIENT TRANSFECTIONS

15 Frozen stocks of cells from passage number six were thawed and expanded to passage number eight before transfections. Confluent cells were trypsinised, washed and pelleted by centrifugation at 270xg for 2 minutes. The cell pellet was resuspended in cold PBS to a cell concentration of about 18×10^6 cells/ml. After addition of DNA, the cell suspension was incubated on ice for approximately 5 minutes before electroporation at 230 V, 960 μ F
 20 in Biorad's Gene Pulser™ in 0.5 ml batches. A total of 50 μ g DNA was added to each batch of 0.5 ml cells, including 2.5 μ g expression vector, 25 μ g reporter vector and 22.5 μ g unspecific DNA (pBluescript, Stratagene).

After electroporation, cells were diluted to a concentration of 320'000 cells/ml in DMEM without phenol red, and approximately 25'000 cells/well were seeded in 96-well plates. In order to allow cells to recover, seeded plates were incubated at 37°C for 3-4 hours before addition of test compounds. In assays for PPAR α , the cell medium was supplemented with 5 resin-charcoal stripped fetal calf serum (FCS) in order to avoid background activation by fatty acid components of the FCS. The resin-charcoal stripped FCS was produced as follows; for 500 ml of heat-inactivated FCS, 10 g charcoal and 25 g Bio-Rad Analytical Grade Anion Exchange Resin 200-400 mesh were added, and the solution was kept on a magnetic stirrer at room temperature over night. The following day, the FCS was 10 centrifuged and the stripping procedure was repeated for 4-6 hours. After the second treatment, the FCS was centrifuged and filter sterilised in order to remove remnants of charcoal and resin.

ASSAY PROCEDURE

Stock solutions of compounds in DMSO were diluted in appropriate concentration ranges 15 in master plates. From master plates, compounds were diluted in culture media to obtain test compound solutions for final doses.

After adjustment of the amount of cell medium to 75 μ l in each well, 50 μ l test compound solution was added. Transiently transfected cells were exposed to compounds for about 24 20 hours before the luciferase detection assay was performed. For luciferase assays, 100 μ l of assay reagent was added manually to each well and plates were left for approximately 20 minutes in order to allow lysis of the cells. After lysis, luciferase activity was measured in a 1420 Multiwell counter, Victor, from Wallach.

Reference compounds

25 The TZD pioglitazone was used as reference substance for activation of both human and murine PPAR γ . 5,8,11,14-Eicosatetrayonic acid (ETYA) was used as reference substance for human PPAR α .

Calculations and analysis

For calculation of EC₅₀ values, a concentration-effect curve was established. Values used were derived from the average of two or three independent measurements (after subtraction of the background average value) and were expressed as the percentage of the maximal activation obtained by the reference compound. Values were plotted against the logarithm of the test compound concentration. EC₅₀ values were estimated by linear intercalation between the data points and calculating the concentration required to achieve 50% of the maximal activation obtained by the reference compound.


5

10 The compounds of formula I have an EC₅₀ of less than 0.5μmol/l for PPAR α and preferred compounds have an EC₅₀ of less than 0.05μmol/l for PPAR α . The compounds of formula I are a select group of compounds in that they are more potent with respect to PPAR α than with respect to PPAR γ . It is believed that this relationship is important with respect to the pharmacological activity of the compounds and to their therapeutic profile.

15 In addition the compounds of the present invention exhibit improved DMPK (Drug Metabolism and Pharmacokinetic) properties for example they exhibit improved metabolic stability *in vitro* and also exhibit favourable dose response curves *in vivo*. The compounds also have a promising toxicological profile.

CLAIMS

1. The S enantiomer of a compound of formula I



5

wherein R¹ represents 2,4-difluorophenyl or cyclohexyl and pharmaceutically acceptable salts, solvates, crystalline forms and prodrugs thereof.

10 2. A compound selected from:

(2*S*)-3-(4-{2-[(Cyclohexylmethyl)(heptyl)amino]-2-oxoethoxy}phenyl)-2-ethoxypropanoic acid ; and

(2*S*)-3-(4-{2-[(2,4-Difluorobenzyl)(heptyl)amino]-2-oxoethoxy}phenyl)-2-ethoxypropanoic acid

15 and pharmaceutically acceptable salts, solvates and crystalline forms thereof.

20 3. 2*S*)-3-(4-{2-[(Cyclohexylmethyl)(heptyl)amino]-2-oxoethoxy}phenyl)-2-ethoxypropanoic acid and pharmaceutically acceptable salts, solvates and crystalline forms thereof.

4. (2*S*)-3-(4-{2-[(2,4-Difluorobenzyl)(heptyl)amino]-2-oxoethoxy}phenyl)-2-ethoxypropanoic acid and pharmaceutically acceptable salts, solvates and crystalline forms thereof.


25 5. A pharmaceutical formulation comprising a compound according to any one of claims 1-4 in admixture with pharmaceutically acceptable adjuvants, diluents and/or carriers.

6. A method of treating or preventing lipid disorders (dyslipidemia) whether or not associated with insulin resistance comprising the administration of a compound according to any one of claims 1-4 to a mammal in need thereof.

5 7. The use of a compound according to any one of claims 1-4 in the manufacture of a medicament for the treatment of lipid disorders (dyslipidemia) whether or not associated with insulin resistance.

10 8. A method of treating or preventing type 2 diabetes comprising the administration of an effective amount of a compound of formula I according to any one of claims 1-4 to a mammal in need thereof.


15 9. A process for the preparation of a compound of formula I comprising reacting a compound of formula II



15

in which R¹ and R² and n are as previously defined and R³ represents a protecting group for carboxylic hydroxy group with a de-protecting agent.


20 10. A compound of formula II



in which R¹ and R² and n are as previously defined and R³ represents a protecting group for carboxylic hydroxy group with a de-protecting agent.

11. A compound of formula III

5



10 in which R² is as previously defined.

12. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 4 combined with another therapeutic agent that is useful in the treatment of disorders associated with the development and progress of atherosclerosis such as hypertension, hyperlipidaemias, dyslipidaemias, diabetes and obesity.

13. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 4 combined with another PPAR modulating agent.

20 14. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 4 combined with a cholesterol-lowering agent.

15. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 4 combined with a HMG-CoA reductase inhibitor.

25

16. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 4 combined with atorvastatin or a pharmaceutically acceptable salt, solvate, crystalline form or prodrug thereof.
17. A pharmaceutical composition comprising a compound as claimed in any one of 5 claims 1 to 4 combined with rosuvastatin or a pharmaceutically acceptable salt thereof.
18. A pharmaceutical composition comprising a compound as claimed in any one of 10 claims 1 to 4 combined with an IBAT inhibitor.
19. A pharmaceutical composition according to claim 18 wherein the IBAT inhibitor is selected from one of:
 - 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)-1'-phenyl-1'-[N'-(carboxymethyl) carbamoyl]methyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
 - 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- α -[N'-(carboxymethyl) carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
 - 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)-1'-phenyl-1'-(2-sulphoethyl) carbamoyl]methyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
 - 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N-{(R)-1'-phenyl-1'-(2-sulphoethyl) carbamoyl]methyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
 - 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- α -[N'-(2-sulphoethyl) carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
 - 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N-{(R)- α -[N'-(2-sulphoethyl) carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;
 - 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N-{(R)- α -[N'-(2-carboxyethyl) carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- α -[N'-(2-carboxyethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N-{(R)- α -[N'-(5-carboxypentyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- α -[N'-(2-carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{ α -[N'-(2-sulphoethyl)carbamoyl]-2-fluorobenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N-{(R)- α -[N'-(R)-(2-hydroxy-1-carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- α -[N'-(R)-(2-hydroxy-1-carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-{N-[{(R)- α -(N'-{(R)-1-[N''-(R)-(2-hydroxy-1-carboxyethyl)carbamoyl]-2-hydroxyethyl}carbamoyl)benzyl}carbamoylmethoxy]-2,3,4,5-tetrahydro-1,5-benzothiazepine};

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N-{ α -[N'-(carboxymethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N-{ α -[N'-(ethoxy)(methyl)phosphoryl-methyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-{N-[{(R)- α -(N'-(2-hydroxy)(methyl)phosphoryl)ethyl}carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- α -[N'-(2-methylthio-1-carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-{N-[{(R)- α -(N'-{2-[(methyl)(ethyl)phosphoryl]ethyl}carbamoyl)-4-hydroxybenzyl]carbamoylmethoxy}-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-{N-[{(R)- α -(N'-{2-[(methyl)(hydroxy)phosphoryl]ethyl}carbamoyl)-4-hydroxybenzyl]carbamoylmethoxy}-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-[(R)- α -[(R)-N'-(2-methylsulphinyl-1-carboxyethyl)carbamoyl]benzyl]carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

10 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methoxy-8-[N-[(R)- α -[N'-(2-sulphoethyl)carbamoyl]-4-hydroxybenzyl]carbamoylmethoxy]-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-[(R)- α -[N-((R)-1-carboxy-2-methylthio-ethyl)carbamoyl]-4-hydroxybenzyl]carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

15 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-[(R)- α -[N-((S)-1-carboxy-2-(R)-hydroxypropyl)carbamoyl]-4-hydroxybenzyl]carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-[(R)- α -[N-((S)-1-carboxy-2-methylpropyl)carbamoyl]-4-hydroxybenzyl]carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

20 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-[(R)- α -[N-((S)-1-carboxybutyl)carbamoyl]-4-hydroxybenzyl]carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-[(R)- α -[N-((S)-1-carboxypropyl)carbamoyl]benzyl]carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

25 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-[(R)- α -[N-((S)-1-carboxyethyl)carbamoyl]benzyl]carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-[(R)- α -[N-((S)-1-carboxy-2-(R)-hydroxypropyl)carbamoyl]benzyl]carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

30 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-[(R)- α -[N-((S)-1-carboxy-2-(R)-hydroxypropyl)carbamoyl]benzyl]carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-(2-sulphoethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxyethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((R)-1-carboxy-2-methylthioethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-[*N*-((S)-2-hydroxy-1-carboxyethyl)carbamoyl]propyl}carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxy-2-methylpropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

15 1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-((S)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-[*N*-(R/S)- α -{*N*-[1-(R)-2-(S)-1-hydroxy-1-(3,4-dihydroxyphenyl)prop-2-yl]carbamoyl}-4-hydroxybenzyl]carbamoylmethoxy]-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

20 2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine; and

1,1-Dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(*N*-{(R)- α -[*N*-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

25 or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

INTERNATIONAL SEARCH REPORT

International Application No PC1/GB 02/05744

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C07C235/20 A61K31/16 A61P3/00		
--	--	--

According to International Patent Classification (IPC) or to both national classification and IPC		
---	--	--

B. FIELDS SEARCHED		
--------------------	--	--

Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07C A61K		
--	--	--

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
---	--	--

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
--	--	--

PAJ, EPO-Internal, CHEM ABS Data		
----------------------------------	--	--

C. DOCUMENTS CONSIDERED TO BE RELEVANT		
--	--	--

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	PATENT ABSTRACTS OF JAPAN vol. 2000, no. 26, 1 July 2002 (2002-07-01) & JP 2001 261612 A (MITSUI CHEMICALS INC), 26 September 2001 (2001-09-26) abstract ---	1,5,7, 12,13
A	WO 00 59889 A (OGUCHI MINORU ; SANKYO CO (JP); FUJITA TAKASHI (JP); HONMA HIDEHITO) 12 October 2000 (2000-10-12) abstract ---	1,5,7, 12,13
A	WO 00 61582 A (OGUCHI MINORU ; SANKYO CO (JP); FUJITA TAKASHI (JP); HONMA HIDEHITO) 19 October 2000 (2000-10-19) abstract ---	1,5,7, 11-13

<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.	<input checked="" type="checkbox"/> Patent family members are listed in annex.
--	--

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
---	--

18 March 2003	28/03/2003
---------------	------------

Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer
--	--------------------

Rufet, J

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 02/05744

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 00 75103 A (KYORIN SEIYAKU KK ;MURAKAMI KOJI (JP); IDE TOMOHIRO (JP); NOMURA M) 14 December 2000 (2000-12-14) abstract ---	1,5,7, 12,13
A,P	WO 02 44130 A (KYORIN SEIYAKU KK ;MURAKAMI KOUJI (JP); NOMURA MASAHIRO (JP); TAKA) 6 June 2002 (2002-06-06) abstract ---	1,5,7, 12,13
A,P	WO 02 44127 A (KYORIN SEIYAKU KK ;MURAKAMI KOUJI (JP); NOMURA MASAHIRO (JP); MIYA) 6 June 2002 (2002-06-06) abstract ---	1,5,7, 12,13
A,P	WO 02 083616 A (SUGAWARA TOMOKADU ;SANKYO CO (JP); ENDO TAKESHI (JP); KUROBE HIROS) 24 October 2002 (2002-10-24) abstract -----	1,5,7, 12,13

INTERNATIONAL SEARCH REPORT

national application No.
PCT/GB 02/05744

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 6 and 8 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition as far as the compounds have been searched.
2. Claims Nos.: 1,10,19 all partially because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of Invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/GB 02 05744

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1,10,19 all partially

Present claims 1, 10 and 19 relate to an extremely large number of possible compounds or pharmaceutical compositions due to the term "prodrug" and the expression "protecting group for carboxylic hydroxy group" comprised in those claims respectively. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds or pharmaceutical compositions claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds of formulae (I) and (II) according to claims 1 and 10 wherein the protecting group is an ester according to page 3 of the description. It is stressed that prodrugs of compounds of formula (I) have not been searched since their structure is not defined nor disclosed.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/GB 02/05744

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
JP 2001261612	A	26-09-2001	NONE		
WO 0059889	A	12-10-2000	AU 3670700 A	23-10-2000	
			BR 0009593 A	18-06-2002	
			CN 1353694 T	12-06-2002	
			CZ 20013593 A3	13-03-2002	
			EP 1167357 A1	02-01-2002	
			HU 0200895 A2	28-11-2002	
			WO 0059889 A1	12-10-2000	
			JP 2001097955 A	10-04-2001	
			NO 20014849 A	27-11-2001	
			TR 200102908 T2	22-04-2002	
WO 0061582	A	19-10-2000	AU 3670900 A	14-11-2000	
			WO 0061582 A1	19-10-2000	
			JP 2000351777 A	19-12-2000	
WO 0075103	A	14-12-2000	JP 2001055367 A	27-02-2001	
			AU 5106700 A	28-12-2000	
			BR 0011734 A	05-03-2002	
			CN 1354742 T	19-06-2002	
			EP 1184366 A1	06-03-2002	
			HU 0201654 A2	28-09-2002	
			WO 0075103 A1	14-12-2000	
			NO 20016001 A	11-02-2002	
			NZ 515705 A	28-02-2003	
			US 6506797 B1	14-01-2003	
WO 0244130	A	06-06-2002	AU 2255002 A	11-06-2002	
			WO 0244130 A1	06-06-2002	
WO 0244127	A	06-06-2002	AU 2255202 A	11-06-2002	
			WO 0244127 A1	06-06-2002	
WO 02083616	A	24-10-2002	WO 02083616 A1	24-10-2002	
			JP 2002371033 A	26-12-2002	